Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.87
+2.3%
$1.04
$0.71
$1.61
$53.22M1.1964,449 shs4.61 million shs
NexGel, Inc. stock logo
NXGL
NexGel
$2.57
+14.2%
$2.42
$2.10
$5.10
$17.22M0.5747,268 shs113,216 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$5.58
-0.2%
$4.82
$4.01
$9.33
$91.93M1.34115,326 shs144,164 shs
Zynex Inc. stock logo
ZYXI
Zynex
$1.26
-43.5%
$2.34
$1.23
$9.42
$67.43M0.91129,129 shs2.27 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
+2.26%-7.88%-13.08%-7.53%-27.57%
NexGel, Inc. stock logo
NXGL
NexGel
+14.22%+8.90%-1.91%-3.38%-18.15%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-0.18%+1.27%+18.72%+28.87%-12.40%
Zynex Inc. stock logo
ZYXI
Zynex
-43.50%-51.16%-53.16%-45.45%-86.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
1.2628 of 5 stars
3.32.00.00.00.60.00.6
NexGel, Inc. stock logo
NXGL
NexGel
0.5341 of 5 stars
0.04.00.00.00.02.50.0
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.3632 of 5 stars
3.53.00.00.00.60.00.0
Zynex Inc. stock logo
ZYXI
Zynex
2.5642 of 5 stars
3.22.00.00.01.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.50
Moderate Buy$5.50532.77% Upside
NexGel, Inc. stock logo
NXGL
NexGel
0.00
N/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$11.67109.08% Upside
Zynex Inc. stock logo
ZYXI
Zynex
2.33
Hold$4.90288.89% Upside

Current Analyst Ratings Breakdown

Latest NXGL, SRTS, ZYXI, and CTSO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Zynex Inc. stock logo
ZYXI
Zynex
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.70
8/1/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/21/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
7/15/2025
Zynex Inc. stock logo
ZYXI
Zynex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.00
6/30/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/25/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
5/2/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$35.60M1.53N/AN/A$0.20 per share4.35
NexGel, Inc. stock logo
NXGL
NexGel
$8.69M2.26N/AN/A$0.90 per share2.86
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M2.19$0.43 per share12.94$3.41 per share1.64
Zynex Inc. stock logo
ZYXI
Zynex
$192.35M0.20$0.14 per share9.13$1.12 per share1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/7/2025 (Estimated)
NexGel, Inc. stock logo
NXGL
NexGel
-$3.28M-$0.45N/AN/A-30.80%-54.95%-27.84%8/18/2025 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1055.8024.26N/A4.56%3.34%3.00%8/7/2025 (Estimated)
Zynex Inc. stock logo
ZYXI
Zynex
$2.99M-$0.24N/A2.68N/A-19.79%-59.71%-15.57%N/A

Latest NXGL, SRTS, ZYXI, and CTSO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2025Q2 2025
NexGel, Inc. stock logo
NXGL
NexGel
-$0.07N/AN/AN/A$3.08 millionN/A
8/7/2025Q2 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.07N/AN/AN/A$9.79 millionN/A
8/7/2025Q2 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.01N/AN/AN/A$9.30 millionN/A
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/14/2025Q1 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million
5/13/2025Q1 2025
NexGel, Inc. stock logo
NXGL
NexGel
-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
NexGel, Inc. stock logo
NXGL
NexGel
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Zynex Inc. stock logo
ZYXI
Zynex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.98
2.61
2.30
NexGel, Inc. stock logo
NXGL
NexGel
0.15
1.88
1.15
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.06
5.74
Zynex Inc. stock logo
ZYXI
Zynex
2.87
3.46
2.63

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
NexGel, Inc. stock logo
NXGL
NexGel
2.21%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Zynex Inc. stock logo
ZYXI
Zynex
29.68%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.30%
NexGel, Inc. stock logo
NXGL
NexGel
20.55%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Zynex Inc. stock logo
ZYXI
Zynex
49.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.61 million58.04 millionOptionable
NexGel, Inc. stock logo
NXGL
NexGel
107.65 million6.08 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable
Zynex Inc. stock logo
ZYXI
Zynex
77030.24 million15.34 millionOptionable

Recent News About These Companies

Zynex, Inc.: Zynex Reports Second Quarter 2025 Financial Results
Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Zynex eyes growth revival under new CEO, advances oximeter technology
Zynex Reports Second Quarter 2025 Financial Results
Zynex Sets Second Quarter 2025 Earnings Call
Zynex: New CEO Steven Dyson shares his vision – ICYMI
Zynex: New CEO Steven Dyson shares his vision – ICYMI
Tricare Temporary Payment Suspension Update
Zynex appoints Steven Dyson as new CEO
Zynex taps Steve Dyson as chief executive officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$0.87 +0.02 (+2.26%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.84 -0.03 (-3.47%)
As of 08/1/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

NexGel stock logo

NexGel NASDAQ:NXGL

$2.57 +0.32 (+14.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.03 (+1.32%)
As of 08/1/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$5.58 -0.01 (-0.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.38 -0.20 (-3.66%)
As of 08/1/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Zynex stock logo

Zynex NASDAQ:ZYXI

$1.26 -0.97 (-43.50%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.27 +0.01 (+1.19%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.